Minakem-flap
Minakem-flap

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find FDA Investigational New Drug (IND) Submissions for Oncology in TAIWAN

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Acepodia

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              TAIWAN Taiwan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI Discover 2021

              Participation Not Confirmed

              Update your events

              Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors

              Contact the Supplier

              Lead Product(s): ACE1702

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 09, 2020

              Details:

              Acepodia received clearance of its Investigational IND application from U.S FDA to start Phase 1 clinical study of its natural killer cell therapy ACE1702 in patients with HER2-expressing solid tumors.

              PharmaCompass__DigitalAd